Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab, Ixazomib, and Dexamethasone in relapsed Multiple Myeloma (DARIA)
NCT03746652Phase 2Unknown
- Sponsor
- Hellenic Society of Hematology
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Overall Response Rate at 36 months. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03746652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746652.